Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.
Urinary excretion of p-hydroxyphenytoin and its glucuronide conjugate was measured in eight healthy young adults in a comparative bioavailability study of oral sodium phenytoin (approximately 5 mg/kg/dose). Among these subjects the percentage of the phenytoin dose converted to p-hydroxyphenytoin and appearing in urine was relatively similar (mean 79%, range 67-88%). The great majority of the p-hydroxyphenytoin appeared in urine as conjugates; only 1.4-3.4% of the excreted p-hydroxyphenytoin was in the form of unconjugated metabolite. The proportion of a single phenytoin dose excreted in urine as p-hydroxyphenytoin or its conjugate increased from the first dose (mean +/- SD) 74.9 +/- 4.6% to the second dose, given 2 weeks later 79.3 +/- 4.6% (p less than 0.05). This finding suggests that autoinduction of phenytoin metabolism may occur after relatively brief exposure to the drug.
D000328:Adult; D001682:Biological Availability; D005260:Female; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D010672:Phenytoin / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000652:urine
D005965:Glucuronates; C001419:hydroxyphenytoin; D010672:Phenytoin